comprehensive -WSS

comprehensive

author：hotspot 2025-10-04 11:57:20 - browse：45534

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： STAT Wunderkinds: Ruey Hu's digital tools for parsing research

leisure time

hotspot

WSS

Diversifying clinical trials isn't enough to close racial gaps: study

Physician assistants need a new name. Here's what it should be

Male doctors called my cancer incurable. A female doctor showed it wasn't

First Opinion Podcast: How to protect health care in times of war

American taxpayers paid $1.8 trillion in health care costs in 2022

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Moonlake's readout produced a cash windfall. Risks remain

First Opinion Podcast: How to protect health care in times of war

Medical leaders decry Supreme Court decision on affirmative action

Biden's order seeks to regulate AI risk without stifling innovation

Hepatitis C has a cure — but many Americans still lack access to it

JPM pitch from hospitals? Revenue streams outside of patient care

Supreme Court strikes down use of affirmative action

In shift, Texas to cover initial consult for Afghan baby's gene therapy

How one medical school became remarkably diverse

Readout Newsletter: What happened with Sarepta's Duchenne data

focus

Arena BioWorks launches in Cambridge to speed drug discovery

Ascension's ugly legal battle over care for poor patients in Texas

Boston Scientific acquires urology company Axonics for $3.7 billion

Physician subsidies by hospitals soar in wake of No Surprises Act

In shift, Texas to cover initial consult for Afghan baby's gene therapy

JPM pitch from hospitals? Revenue streams outside of patient care

leisure time

focus

hotspot

knowledge